serological testing and treatment for plasmodium vivax malaria: a trial in ethiopia and madagascar

Conditions: Malaria Vivax; Malaria Falciparum; Plasmodium Vivax; Plasmodium Falciparum

Summary: the resilience of p. vivax to malaria elimination efforts is due to its ability to form dormant liver stages (hypnozoites) that reactivate weeks to months after the initial infection causing recurrent episodes of malaria (relapses) and ongoing parasite transmission. relapses account for a majority of recurrent infections and clinical cases of p. vivax malaria, and therefore have a significant effect on morbidity at the individual level. with current technology, it is not possible to directly measure hypnozoite biomarkers. rather than directly detecting hypnozoites, our team developed an indirect approach by measuring antibodies induced by the primary blood-stage infection. antibodies to different blood-stage antigens decay at different rates. measuring antibodies to a carefully selected panel of p. vivax antigens can aid to identify individuals who have been infected within the previous 9 months (approximately the lifespan of hypnozoites). a serological test based on selected p. vivax antigens can detect recent exposure and predict future relapses. coupling this test with a safe and efficacious primaquine treatment regimen, results in a population-based intervention to target the hypnozoite reservoir. this intervention is referred to as plasmodium vivax serological testing and treatment (pvserotat). pvstatem is a cluster randomised trial in madagascar and ethiopia. this study will provide insights into the feasibility, acceptability, and efficacy of the pvserotat approach. in this study, individuals, randomised by clusters, will be tested for the presence of serological markers of a recent p. vivax infection, followed by a targeted drug treatment intervention aimed at killing p. vivax hypnozoites.

in each country, 24 clusters (48 clusters in total) will be randomly allocated using computer generated numbers to one of the two interventions: arm 1 (pvserotat intervention) or arm 2 (control arm). within each cluster, approximately 400 participants (range 100-600) will be enrolled, based on the trial's inclusion and exclusion criteria. at baseline (month 0) and month 6 serology for p. vivax infections will be performed in all study participants. in the clusters in the pvserotat arm, participants with a positive p. vivax serology at baseline or month 6 will be approached for treatment. first g6pd enzyme activity will be measured. if the enzyme activity is normal and no other contra-indication for treatment are found, the participants will be treated with 7 days of primaquine 0.5mg/kg/day and a three-day course of either chloroquine (ethiopia) or artesunate-amodiaquine (madagascar). it is possible that a participant could receive a radical p. vivax treatment at both baseline (month 0) and month 6. participants will be monitored for side effects and adherence during the first 7 days after the start of antimalarial treatments. in addition, blood samples will be taken to measure hemoglobin levels to monitor for post-treatment hemolysis. in the clusters in both arms, the incidence of malaria will be monitored through passive case detection in health posts up to 18 months after the first intervention. all cases that are detected during the passive case detection will be treated according to the national guidelines. at month 12 and month 18 of the study, a cross sectional survey will be conducted in all study clusters. blood samples will be taken to determine the prevalence of p. vivax and p. falciparum through pcr assays.

Eligibility criteria:
inclusion criteria: * participant will remain in the study area for at least the next month. * participant is older than 12 months exclusion criteria: • participant is unwilling to participate.

Keywords: plasmodium vivax vivax pvserotat pvstatem primaquine serology cluster randomised trial g6pd